Business
PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer
Dr. Tweezer-Zaks Transitions from the Company’s Board of Directors to Lead Medical Strategy Following Positive Phase 3 Results and Expanding PipelinePETACH TIKVA, Israel, Aug. 12, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Dr. Nurit Tweezer-Zaks, M.D., M.B.A., as Chief Medical Officer, effective as of August 18, 2025. Dr. Tweezer-Zaks, who has served on P
About this update from Polypid Ltd.
[{"type":"image","alt":"PolyPid Ltd.","displaySize":"","headline":null,"caption":"PolyPid Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":140,"url":"https://media.zenfs.com/en/globenewswire.com/fdc21f8c528080a8e08cb717b24cf2fd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/p.GVrjAO9AQ10s3m1PTgIg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/fdc21f8c528080a8e08cb717b24cf2fd","width":300,"height":140}},"lazy":false},{"type":"text","content":"Dr. Tweezer-Zaks Transitions from the Company’s Board of Directors to Lead Medical Strategy Following Positive Phase 3 Results and Expanding Pipeline","length":149,"tagName":"p"},{"type":"text","content":"PETACH TIKVA, Israel, Aug. 12, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Dr. Nurit Tweezer-Zaks, M.D., M.B.A., as Chief Medical Officer, effective as of August 18, 2025. Dr. Tweezer-Zaks, who has served on PolyPid's Board of Directors (the “Board”) since November 2023, will step down from the Board, effective as of August 17, 2025 as she assumes this new executive role.","length":545,"tagName":"p"},{"type":"text","content":""We are delighted to welcome Dr. Tweezer-Zaks to the executive team at this pivotal time for PolyPid following our positive Phase 3 SHIELD II trial results," said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. "Her extensive medical expertise, deep understanding of our technology platform, and broad industry experience make her ideally suited to lead our medical strategy as we prepare for our upcoming New Drug Application (NDA) submission and advance our pipeline. Having worked closely with Dr. Tweezer-Zaks during her tenure on our Board, I am confident that her leadership will be invaluable as we enter this exciting new phase for the Company."","length":687,"tagName":"p"},{"type":"text","content":"Dr. Tweezer-Zaks brings to PolyPid extensive executive, medical, and research and development expertise. Prior to joining PolyPid, she served as Chief Executive Officer of MediCane Health Inc., a fully integrated global medical cannabis company. Previously, Dr. Tweezer-Zaks held senior positions at aMOON...